CHARLESSON, LLP

Address

800 Research Parkway
OKLAHOMA CITY, OK, 73104-3611

Information

DUNS: 143171531
# of Employees: 10

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y

Award Charts




Award Listing

  1. Fenofibrate Eye Drop for the Treatment of Diabetic Retinopathy

    Amount: $185,550.00

    DESCRIPTION provided by applicant This Small Business Innovation Research project aims to develop an innovative eye drop formulation for the treatment of diabetic retinopathy The goal of this prop ...

    SBIRPhase I2016Department of Health and Human Services
  2. A Novel Therapeutic Antibody for Age-related Macular Degeneration

    Amount: $225,000.00

    DESCRIPTION provided by applicant Age related macular degeneration AMD is a common disease of the central retina and remains a leading cause of vision loss and blindness in elderly Americans Cur ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  3. Developing A Novel Therapy for Diabetic Retinopathy

    Amount: $1,495,545.00

    DESCRIPTION provided by applicant Diabetic retinopathy DR is a common complication of diabetes and a leading cause of vision loss in the United States Although the anti vascular endothelial grow ...

    SBIRPhase II2015Department of Health and Human Services
  4. A Wnt Modulator for Treatment of Age-related Macular Degeneration

    Amount: $225,000.00

    PROJECT SUMMARY/ABSTRACT Age-related macular degeneration (AMD) is characterized by progressively decreased central vision and visual acuity and remains a leading cause of vision loss and blindness i ...

    SBIRPhase I2014Department of Health and Human Services
  5. Developing A Novel Therapy for Diabetic Retinopathy

    Amount: $246,418.00

    DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of vision loss in the United States. Unfortunately, there is no FDA-approved pha ...

    SBIRPhase I2013Department of Health and Human Services
  6. A Small Molecule Targeting Wnt Pathway for Treatment of Diabetic Retinopathy

    Amount: $231,087.00

    DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of blindness. This sight-threatening condition has become a public health challe ...

    SBIRPhase I2012Department of Health and Human Services
  7. Multitargeted Therapy for Age-related Macular Degeneration

    Amount: $265,992.00

    DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a sight-threatening disease which represents the leading cause of blindness and visual impairment in elderly individu ...

    SBIRPhase I2011Department of Health and Human Services
  8. Novel emulsion-based formulation of the anti-glaucoma MSH-1001 for improved topic

    Amount: $287,947.00

    DESCRIPTION (provided by applicant): This Small Business Innovation project aims to develop an innovative eye drop formulation for the treatment of glaucoma and ocular hypertension. Charlesson has acq ...

    SBIRPhase I2011Department of Health and Human Services
  9. Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed

    Amount: $2,685,795.00

    DESCRIPTION (provided by applicant): The objective of this proposal is to finalize development of CLT-005, a novel small molecule inhibitor of Stat3, through the performance of studies required fo ...

    SBIRPhase II2011Department of Health and Human Services
  10. Novel Antioxidants for Treatment of Diabetic Retinopathy

    Amount: $248,094.00

    DESCRIPTION (provided by applicant): Diabetic retinopathy is a common complication of diabetes mellitus and a leading cause of severe vision loss and blindness around the world. The current interventi ...

    SBIRPhase I2009Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government